F&V Capital Management LLC grew its holdings in shares of Celgene Co. (NASDAQ:CELG) by 16.3% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 6,880 shares of the biopharmaceutical company’s stock after buying an additional 965 shares during the quarter. F&V Capital Management LLC’s holdings in Celgene were worth $718,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Capital Counsel LLC NY boosted its holdings in shares of Celgene by 0.4% in the second quarter. Capital Counsel LLC NY now owns 1,649 shares of the biopharmaceutical company’s stock valued at $214,000 after purchasing an additional 6 shares during the period. Fort Pitt Capital Group LLC boosted its holdings in shares of Celgene by 0.6% in the second quarter. Fort Pitt Capital Group LLC now owns 1,925 shares of the biopharmaceutical company’s stock valued at $250,000 after purchasing an additional 11 shares during the period. Savant Capital LLC boosted its holdings in shares of Celgene by 0.9% in the second quarter. Savant Capital LLC now owns 2,350 shares of the biopharmaceutical company’s stock valued at $305,000 after purchasing an additional 20 shares during the period. TCI Wealth Advisors Inc. boosted its holdings in shares of Celgene by 0.9% in the second quarter. TCI Wealth Advisors Inc. now owns 3,043 shares of the biopharmaceutical company’s stock valued at $395,000 after purchasing an additional 26 shares during the period. Finally, Linscomb & Williams Inc. boosted its holdings in shares of Celgene by 1.0% in the second quarter. Linscomb & Williams Inc. now owns 3,813 shares of the biopharmaceutical company’s stock valued at $495,000 after purchasing an additional 36 shares during the period. 78.93% of the stock is currently owned by hedge funds and other institutional investors.

In other Celgene news, insider Mark J. Alles acquired 3,260 shares of the firm’s stock in a transaction dated Thursday, February 8th. The stock was purchased at an average price of $91.90 per share, for a total transaction of $299,594.00. Following the acquisition, the insider now owns 178,904 shares in the company, valued at approximately $16,441,277.60. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.95% of the company’s stock.

Shares of Celgene Co. (NASDAQ:CELG) opened at $92.51 on Friday. Celgene Co. has a twelve month low of $88.32 and a twelve month high of $147.17. The company has a current ratio of 4.99, a quick ratio of 3.52 and a debt-to-equity ratio of 2.29. The company has a market capitalization of $68,463.02, a price-to-earnings ratio of 25.84, a PEG ratio of 0.65 and a beta of 1.49.

Celgene (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, January 25th. The biopharmaceutical company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.78 by $0.09. Celgene had a return on equity of 67.50% and a net margin of 22.38%. The firm had revenue of $3.48 billion during the quarter, compared to analyst estimates of $3.46 billion. During the same quarter in the prior year, the business posted $1.61 EPS. The business’s revenue for the quarter was up 16.9% compared to the same quarter last year. sell-side analysts expect that Celgene Co. will post 7.68 earnings per share for the current year.

CELG has been the subject of a number of research reports. UBS Group lowered their price target on Celgene from $153.00 to $146.00 and set a “buy” rating for the company in a report on Friday, October 20th. Stifel Nicolaus lowered their price target on Celgene from $155.00 to $149.00 and set a “buy” rating for the company in a report on Friday, October 20th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Celgene in a report on Monday, October 16th. Jefferies Group reiterated a “buy” rating and issued a $160.00 price target on shares of Celgene in a report on Monday, October 16th. Finally, Cantor Fitzgerald set a $162.00 price target on Celgene and gave the company a “buy” rating in a report on Monday, October 16th. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $130.35.

TRADEMARK VIOLATION NOTICE: This story was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.watchlistnews.com/fv-capital-management-llc-has-718000-stake-in-celgene-co-celg/1856907.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.